Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
emavusertib (CA-4948)
i
Other names:
CA4948, AU4948, CA-4948, AU 4948, CA 4948, AU-4948
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(6)
News
Trials
Company:
Curis, Dr. Reddy’s
Drug class:
IRAK-4 inhibitor
Related drugs:
‹
HPB-092 (2)
KTX-582 (0)
ND-2110 (0)
R289 (0)
PF-06650833 (0)
HPB-092 (2)
KTX-582 (0)
ND-2110 (0)
R289 (0)
PF-06650833 (0)
›
Associations
(6)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (NCT06439836)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not yet recruiting
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
02/18/2025
Initiation :
02/21/2025
Primary completion :
06/01/2027
Completion :
06/01/2027
PD-L1 • CD68 • CRP
|
PD-L1 expression
|
Keytruda (pembrolizumab) • emavusertib (CA-4948)
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (NCT06696768)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not yet recruiting
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
01/16/2025
Initiation :
02/28/2025
Primary completion :
10/31/2025
Completion :
10/31/2025
IFNG • IL6 • CCL2 • CXCL1 • IRAK4
|
Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS (NCT04278768)
Phase 1/2
Curis, Inc.
Curis, Inc.
Recruiting
Phase 1/2
Curis, Inc.
Recruiting
Last update posted :
03/11/2024
Initiation :
07/06/2020
Primary completion :
04/01/2026
Completion :
04/01/2026
FLT3 • SF3B1 • U2AF1
|
FLT3 mutation • SF3B1 mutation • U2AF1 mutation
|
Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (NCT05187182)
Phase 1
Washington University School of Medicine
Washington University School of Medicine
Recruiting
Phase 1
Washington University School of Medicine
Recruiting
Last update posted :
12/04/2023
Initiation :
06/02/2023
Primary completion :
09/30/2026
Completion :
06/30/2027
HER-2
|
HER-2 positive • HER-2 negative
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • emavusertib (CA-4948)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login